



# WINTER RESPIRATORY VIRUSES IN EUROPE

## POLICY BRIEF

COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumococcal disease, and Human Metapneumovirus (hMPV)



**ESWI**

SCIENTISTS FIGHTING  
INFLUENZA AND  
OTHER ACUTE  
RESPIRATORY VIRUSES

# Executive Summary

*Achieving  $\geq 75\%$  influenza and  $\geq 50\%$  COVID-19 booster coverage among adults aged 65 years or older could prevent approximately 250,000 hospitalisations and save €2–3 billion annually [9,10]. Every percentage-point gain in uptake strengthens Europe's ability to manage future respiratory threats.*

**Europe's ageing and increasingly mobile population faces a persistent winter burden of respiratory viruses.**

Influenza, COVID-19, RSV, and pneumococcal disease remain major causes of hospitalisation and death, particularly among adults aged  $\geq 60$  years and those with chronic cardiorespiratory, metabolic, or immune conditions [1–3]. Seasonal surges stretch hospitals, disrupt the workforce, and threaten older and clinically vulnerable citizens.

**Vaccination is Europe's most effective and equitable preventive investment.**

Influenza vaccination coverage in adults  $\geq 65$  years averaged 47% across EU/EEA countries in 2023, ranging from  $<20\%$  to  $>75\%$  [4]. During 2024/25, COVID-19 booster uptake among adults  $\geq 60$  years was only 7–9% across reporting Member States [5].

RSV vaccines are newly authorised for adult use [6], and pneumococcal schedules have simplified with single-visit PCV20 protection [7]. The European Respiratory Virus Surveillance Summary (ERVISS) platform now coordinates timing, performance, and transparent communication [8].

**A single, coordinated autumn campaign** – covering influenza and COVID-19 for all eligible adults, RSV for individuals aged 75 and older and those at risk aged 60–74, and opportunistic PCV20 – would deliver prevention at scale. Pharmacy delivery, long-term-care-facility (LTCF) in-reach, and mobile outreach can close equity gaps while maintaining subsidiarity.

# The Life Course Approach

**Vaccination across the life course protects people at every stage of life and embeds prevention into routine care.**

A life-course approach ensures continuity of protection as individuals age, move, or acquire new health conditions [11]. It protects those who cannot be vaccinated through sustained community immunity and recognises increasing migration and mobility across Europe [12]. Connecting data through the European Health Data Space (EHDS) unites coordination and independence.

The EHDS enables Member States to link national immunisation registries while retaining autonomy over financing and delivery [13]. Shared, interoperable data allows benchmarking, equity monitoring, and rapid outbreak response without centralisation. Life-course immunisation strengthens Europe's workforce and economy.

Preventing illness in working-age adults reduces absenteeism and productivity losses estimated at €1 billion annually for influenza alone [14]. Healthier ageing reduces long-term care costs and dependency, delivering measurable fiscal and social benefits [15].



# COVID-19

*Seasonal COVID-19 vaccination is essential to protect Europe's ageing and mobile population. Achieving a booster uptake of over 60% among adults aged 65 years and above could prevent around 30,000 deaths and more than 100,000 hospitalisations annually [5,9]. Integrating boosters within life-course programmes converts emergency responses into predictable prevention, preserving workforce stability and health system resilience.*

## **COVID-19 remains a serious seasonal threat despite endemic circulation.**

Older and multi-morbid adults continue to experience disproportionate morbidity and mortality. During 2024/25, median booster coverage among adults  $\geq 60$  years across EU/EEA countries was 7–9%, with considerable national variation [5]. The overlapping COVID-19 and influenza waves exacerbate hospital and ICU strain [1,8].

## **Normalising COVID-19 vaccination within life-course immunisation ensures continuity of protection.**


Embedding boosters in the annual respiratory-virus offer – co-administered with influenza and RSV – simplifies access for ageing, mobile, and vulnerable populations [16]. Real-time registry uploads through pharmacies and LTCFs enable transparent monitoring and targeted outreach [8].

## **Recommendations**

- Codify seasonal boosters for  $\geq 65$  and defined risk groups, with default co-administration alongside influenza (and RSV where indicated).
- Remunerate pharmacy vaccination and require real-time registry upload; conduct on-site LTCF clinics from September.
- Report weekly indicators (coverage, positivity, hospitalisations, ICU) and publish monthly plain-language vaccine-effectiveness and safety briefs.
- Use flexible procurement and agile strain updates to safeguard supply without over-ordering.




# COVID-19



COVID-19 vaccination coverage over-60s across EU/EEA countries 1 August 2024-28 March 2025 | [ECDC, 2025](#)

# Influenza

*Achieving  $\geq 75\%$  coverage among adults aged  $\geq 65$  years could prevent approximately 20,000 deaths, 250,000 hospitalisations, and over €1 billion in medical costs each winter [9, 17, 20]. Influenza vaccination protects those who cannot be vaccinated, sustains independence in later life, and relieves winter pressure on Europe's healthcare workforce.*



Over-65 Influenza Vaccination Coverage Rates in EU Member States | [Eurostat 2024](#)

**Influenza remains a predictable, preventable, and under-controlled winter burden across Europe.**

It causes roughly 27,600 respiratory deaths annually in the EU/EEA, mostly among older adults with chronic disease [4,17]. The average vaccination coverage among adults aged 65 years and above stands at 47%, far below the EU benchmark of 75% [4].

# Influenza

## **Embedding influenza vaccination within routine adult and chronic-disease care ensures equitable protection.**

Offering vaccinations during COPD, diabetes, and cardiovascular reviews in community pharmacies and at hospital discharge supports lifelong protection and convenience [18]. Co-administration with other adult vaccines (COVID-19, RSV, pneumococcal) should be the default. Digital reminders, multilingual materials, and trusted professional communication improve uptake among sedentary and mobile populations [19].

### **Recommendations**

- Set and publish a  $\geq 75\%$  target for adults  $\geq 65$  years and track weekly progress using ECDC ERVISS data.
- Make GP/pharmacist-to-patient education the campaign backbone: brief consults, translated materials, targeted text reminders.
- Integrate influenza vaccination into chronic-disease reviews; recall if out of season.
- Remunerate pharmacists for administration and require real-time registry upload.
- Normalise co-administration with other indicated vaccines to minimise repeat visits.
- Advance EU-level uniformity in risk-group definitions, funding, and coverage metrics; progress toward a pan-EU digital vaccination record.

# Respiratory Syncytial Virus (RSV)

*Closing the adult RSV prevention gap protects Europe's frailest citizens and relieves winter pressure. Achieving 60% coverage in eligible adults could avert tens of thousands of hospitalisations and save hundreds of millions of euros annually [21,27].*

**RSV is a significant but historically under-recognised cause of severe adult respiratory disease.**

Across the EU, modelling estimates about 158,000 RSV-associated hospitalisations in adults annually, with more than 90% occurring in those  $\geq 65$  years [21]. Hospitalised older adults have high ICU admission rates and substantial post-discharge mortality; systematic under-testing contributes to under-ascertainment [22].

**Authorised adult RSV vaccines enable targeted protection.**

The EMA has approved RSV vaccines for older adults, and the European Commission extended the approval to risk groups aged 18–59 years in 2025 [23,24]. Germany's STIKO and France's HAS recommend vaccination for those  $\geq 75$  years and for 60–74 years at risk [25,26]. Early evidence from Scotland shows a reduction in older-adult hospitalisations following the rollout [27].


## Recommendations

- Offer RSV vaccination to  $\geq 75$  years and 60–74 years with risk conditions; start each September with LTCF in-reach and pharmacy delivery.
- Co-administer with influenza/COVID-19 where indicated and communicate safety and effectiveness transparently.
- Publish monthly plain-language safety briefs and early real-world effectiveness summaries.
- Integrate adult RSV surveillance with age, comorbidity, ICU, ventilation, and mortality data to support annual cost-effectiveness reviews.



# Pneumococcal Disease

*Preventing pneumococcal complications reduces admissions, shortens stays, and cuts antibiotic exposure that drives AMR. Achieving 70% adult coverage with PCV20 could prevent more than 100,000 hospitalisations annually across Europe [30–32].*



**Pneumococcal Vaccination Coverage for Adults (2023)** | Pneumococcal Vaccination Atlas

# Pneumococcal Disease

*Streptococcus pneumoniae* amplifies viral-season harm through secondary pneumonia and invasive disease in older and multimorbid adults [30]. Simplified adult schedules such as PCV20 enable single-visit protection and opportunistic delivery.

Multiple Member States recommend PCV20 for adults  $\geq 60/65$  years and at-risk groups, broadening serotype coverage and aligning with life-course principles [31,32].

## Recommendations

- Standardise simple adult schedules (PCV20 for  $\geq 65$  years and defined risk groups) with co-administration alongside influenza/COVID-19/RSV.
- Build prompts into chronic-disease reviews and discharge bundles; ensure registry reminders in GP/pharmacy systems.
- Use multi-year tenders with clear interchangeability to stabilise supply; publish adult coverage annually.

# Human Metapneumovirus (hMPV)

*Recognising and tracking hMPV now prevents hidden winter pressures and shortens the path from future product authorisation to equitable access [33–36].*

hMPV is an overlooked contributor to winter respiratory illness in older and immunocompromised adults.

ECDC reports hMPV peaks from late winter to spring and causes clinically significant disease; there is currently no vaccine or antiviral [33]. WHO and ECDC call for integrated surveillance to include hMPV alongside influenza, RSV, and SARS-CoV-2 [34–36].

Preparing now ensures rapid evaluation when vaccines or antivirals become available. Including hMPV in dashboards, outbreak protocols for LTCFs, and multiplex PCR testing frameworks positions Member States for rapid HTA and JCA once candidates progress [35,36].

## Recommendations

- Include hMPV in national integrated respiratory surveillance with age-stratified positivity and severity metrics.
- Expand multiplex PCR testing for severe ARI in hospitals and LTCFs.
- Treat hMPV operationally like RSV/influenza in LTCF outbreak protocols.
- Prepare HTA/JCA templates in advance for future vaccine evaluation.

# Conclusion

**Prevention across the life course is Europe's route from seasonal crisis to sustainable winter resilience.**

A connected, annual adult respiratory offer – covering influenza, COVID-19, RSV, and pneumococcal vaccination – protects ageing, mobile, and clinically vulnerable populations while safeguarding system capacity and the workforce [8,21,31,33].

Scaling adult vaccination now yields measurable returns: fewer admissions and deaths, reduced antimicrobial use, and stronger, steadier health-system performance each winter [9,21,30–36].



# REFERENCES

1. WHO Europe. *Integrated surveillance of respiratory viruses in Europe 2025 update*. Copenhagen; 2025.
2. ECDC. *Annual Epidemiological Report 2024 – Respiratory viruses*. Stockholm; 2025.
3. OECD & European Commission. *Health at a Glance: Europe 2024*. Paris; 2024.
4. Eurostat. *Influenza vaccination coverage rate (hlth\_ps\_immu)*. Data extracted 2024.
5. ECDC. *COVID-19 vaccination coverage in the EU/EEA 2024–2025 season*. Interim update, Jan 2025.
6. EMA. *Abrysvo and Arexvy Public Assessment Reports*. 2024–2025.
7. ECDC Vaccine Scheduler. *Pneumococcal vaccination recommendations for adults in the EU/EEA*. 2025.
8. ECDC. *European Respiratory Virus Surveillance Summary (ERVISS) Protocol*. 2025.
9. ECDC. *Impact of influenza and COVID-19 vaccination on hospitalisations and deaths in older adults – EU/EEA model*. 2024.
10. WHO Europe. *Economic case for adult vaccination in Europe*. 2024.
11. Coalition for Life-Course Immunisation. *Life-Course Immunisation Summit Report*. 2023.
12. European Commission. *Population mobility and migration in Europe 2024 report*. 2024.
13. European Commission. *European Health Data Space Regulation (COM/2022/197)*. 2024.
14. ECDC. *Influenza vaccination and economic burden report*. 2023.
15. OECD. *Healthy Ageing and Long-Term Care Outlook 2024*. 2024.
16. WHO Europe. *COVID-19 vaccination: guidance for integrating boosters into routine immunisation*. 2024.
17. ECDC. *Burden of influenza in the EU/EEA – estimates for older adults*. 2023.
18. WHO Europe. *Strengthening adult immunisation in primary care settings*. 2023.
19. ECDC. *Behavioural insights and vaccination communication toolkit*. 2024.
20. WHO Europe. *Influenza vaccination: health-economic evidence summary*. 2024.
21. Osei-Yeboah R et al. *Estimation of RSV-associated hospitalisations in adults in the EU*. J Infect Dis. 2023.
22. WHO/ECDC. *Joint European respiratory virus surveillance guidance*. 2025.
23. EMA. *Abrysvo – EPAR (adult indications)*. 2025.
24. European Commission. *EC approval of Abrysvo extension to adults 18–59 at risk*. Apr 2025.
25. STIKO (RKI). *Epidemiologisches Bulletin 04/2025 – RSV in older adults*. 2025.
26. HAS (France). *Stratégie vaccinale VRS chez l'adulte ≥60 ans*. 2024.
27. Hameed SS et al. *Early evidence of RSV vaccination impact on hospitalisation rates of older people in Scotland*. Lancet Infect Dis. 2025.
28. ECDC. *Antimicrobial resistance in the EU/EEA – Surveillance & burden overview*. 2025.
29. ECDC Vaccine Scheduler. *Pneumococcal vaccination overview*. 2025.
30. Chiavarini M et al. *Pneumococcal vaccination offers and schedules across EU*. 2025.
31. ECDC. *Increase in respiratory infections – hMPV note*. Jan 2025.
32. WHO. *Disease Outbreak News: Acute respiratory infection trends*. Jan 2025.
33. ECDC. *Reporting protocol for integrated respiratory virus surveillance in Europe*. Sept 2025.
34. WHO Europe & ECDC. *Joint European respiratory virus surveillance meeting – Expanded integrated surveillance statements*. Jun 2025.

DEVELOPED BY